Celestia Higano
Celestia Higano
Підтверджена електронна адреса в u.washington.edu
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
PW Kantoff, CS Higano, ND Shore, ER Berger, EJ Small, DF Penson, ...
New England Journal of Medicine 363 (5), 411-422, 2010
Abiraterone in metastatic prostate cancer without previous chemotherapy
CJ Ryan, MR Smith, JS De Bono, A Molina, CJ Logothetis, P De Souza, ...
New England Journal of Medicine 368 (2), 138-148, 2013
Enzalutamide in metastatic prostate cancer before chemotherapy
TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ...
New England Journal of Medicine 371 (5), 424-433, 2014
Development of a second-generation antiandrogen for treatment of advanced prostate cancer
C Tran, S Ouk, NJ Clegg, Y Chen, PA Watson, V Arora, J Wongvipat, ...
Science 324 (5928), 787-790, 2009
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical …
HI Scher, S Halabi, I Tannock, M Morris, CN Sternberg, MA Carducci, ...
Journal of clinical oncology: official journal of the American Society of …, 2008
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
EJ Small, PF Schellhammer, CS Higano, CH Redfern, JJ Nemunaitis, ...
Journal of Clinical Oncology 24 (19), 3089-3094, 2006
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth
RB Montgomery, EA Mostaghel, R Vessella, DL Hess, TF Kalhorn, ...
Cancer research 68 (11), 4447-4454, 2008
Guideline for the management of clinically localized prostate cancer: 2007 update
I Thompson, JB Thrasher, G Aus, AL Burnett, ED Canby-Hagino, ...
The Journal of urology 177 (6), 2106-2131, 2007
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
HI Scher, TM Beer, CS Higano, A Anand, ME Taplin, E Efstathiou, ...
The Lancet 375 (9724), 1437-1446, 2010
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall …
CJ Ryan, MR Smith, K Fizazi, F Saad, PFA Mulders, CN Sternberg, ...
The Lancet Oncology 16 (2), 152-160, 2015
Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer
CS Higano, PF Schellhammer, EJ Small, PA Burch, J Nemunaitis, L Yuh, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2009
Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized …
MS Cookson, G Aus, AL Burnett, ED Canby-Hagino, AV D’Amico, ...
The Journal of urology 177 (2), 540-545, 2007
Quantitative and stoichiometric analysis of the microRNA content of exosomes
JR Chevillet, Q Kang, IK Ruf, HA Briggs, LN Vojtech, SM Hughes, ...
Proceedings of the National Academy of Sciences 111 (41), 14888-14893, 2014
Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B
Y Sun, J Campisi, C Higano, TM Beer, P Porter, I Coleman, L True, ...
Nature medicine 18 (9), 1359-1368, 2012
Prostate cancer, version 1.2016
JL Mohler, AJ Armstrong, RR Bahnson, AV D'Amico, BJ Davis, ...
Journal of the National Comprehensive Cancer Network 14 (1), 19-30, 2016
Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3
HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ...
Journal of Clinical Oncology 34 (12), 1402, 2016
Intermittent versus continuous androgen deprivation in prostate cancer
M Hussain, CM Tangen, DL Berry, CS Higano, ED Crawford, G Liu, ...
New England Journal of Medicine 368 (14), 1314-1325, 2013
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
SF Slovin, CS Higano, O Hamid, S Tejwani, A Harzstark, JJ Alumkal, ...
Annals of Oncology 24 (7), 1813-1821, 2013
PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine
MA Cheever, CS Higano
Clinical Cancer Research 17 (11), 3520-3526, 2011
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest …
M Hussain, CM Tangen, C Higano, PF Schelhammer, J Faulkner, ...
Journal of clinical oncology 24 (24), 3984-3990, 2006
У даний момент система не може виконати операцію. Спробуйте пізніше.
Статті 1–20